Mr. Freeze: Biden’s Swift Move To Pause Last-Minute Trump-Era Regs

US Regulatory Roundup, January 2021

A raft of rules that affect the medtech industry are on ice for the time being while the new Biden administration determines whether the regulations should move forward. This and other stories topped our list of most-read Medtech Insight articles in January.

Top Stories US

A raft of rules that affect the medtech industry are paused for the time being while the new Biden administration determines whether the regulations should indeed move forward. Our reporting on Biden’s reg freeze, and the rules it touches, was of most interest to Medtech Insight readers last month.

A memo from the White House on 20 January – Inauguration Day – to the heads of executive departments requested that they “consider” suspending action on any so-called “midnight...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financial Shortcomings — Remain In Women’s Health, Execs Say

 

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By 

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.